Primary Objective:~• To determine the efficacy of sacituzumab govitecan and pembrolizumab combination treatment on pathological complete response (pCR)/residual cancer burden (RCB)-1 in the patients with early-stage TNBC who showed a resistance to the combination of immunochemotherapy.~Secondary Objectives:~To determine the safety of the proposed combination treatment.~To determine the objective overall response rate (ORR) of the proposed treatment.~To determine the distant-recurrence-free survival (DRFS).~To determine the 3-year event-free survival (EFS) rate.~To determine the 3-year overall survival (OS) rate.~Exploratory Objective:~• To investigate the response biomarkers in the tumor tissues and peripheral blood.
To learn if sacituzumab govitecan and pembrolizumab, when given before surgery, can help to control early-stage triple negative breast cancer that has not responded well to other treatments.